Trading risks for markets: the international harmonisation of pharmaceuticals regulation

被引:42
作者
Abraham, J [1 ]
Reed, T [1 ]
机构
[1] Univ Sussex, Sch Social Sci, Ctr Res Hlth & Med, Sociol Subject Grp, Brighton BN1 9SN, E Sussex, England
关键词
drugs; pharmaceutical regulation; safety; harmonisation; drug industry; risk and globalisation;
D O I
10.1080/713670172
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Drawing on interviews and documentary research, this paper explores the nature of international hramonisation of pharmaceutical regulation. The relationships between international harmonisation, trade interests in market expansion and the regulatory state are examined. Particular attention is given to the implications of this harmonisation for drug safety, risk assessment and public health. It is argued that this process is lowering regulatory standards regarding drug safety and is making the regulatory state more vulnerable to capture by industrial Interests. This Is accentuated by the misrepresentation of societal and political judgements as technical calculations and a concomitant lack of public accountability.
引用
收藏
页码:113 / 128
页数:16
相关论文
共 51 条
[1]   NEGOTIATION AND ACCOMMODATION IN EXPERT MEDICAL RISK ASSESSMENT AND REGULATION - AN INSTITUTIONAL ANALYSIS OF THE BENOXAPROFEN CASE [J].
ABRAHAM, J .
POLICY SCIENCES, 1994, 27 (01) :53-76
[2]  
Abraham J., 1995, SCI POLITICS PHARM I
[3]  
Abraham J., 2000, Regulating medicines in Europe
[4]  
ABRAHAM J, 1999, THERAPEUTIC NIGHTMAR
[5]  
[Anonymous], 1992, SCRIP, V1707, P14
[6]  
[Anonymous], KEY ISSUES PHARM IND
[7]  
Araga Y., 1996, P 3 INT C HARM BELF
[8]  
Bangemann M., 1992, P 1 INT C HARM BELF
[9]  
BROWN JS, 1996, DRUG INF J, V30, P17
[10]  
Cecchini P, 1988, EUROPEAN CHALLENGE 1